Hong Kong Turns Healthcare Into Industrial Strategy at ASGH 2026

The 2026 edition of the Asia Summit on Global Health (ASGH) opened in Hong Kong today with a message that extended well beyond pandemic preparedness or biotechnology investment alone: healthcare has become infrastructure, industrial policy, and geopolitical strategy at the same time.

Held as part of Hong Kong’s International Healthcare Week, the summit brought together policymakers, pharmaceutical companies, investors, clinicians, regulators, and research institutions to discuss how governments and industry are restructuring healthcare systems after COVID-19. The event focused heavily on cross-border clinical research, AI-driven healthcare, regulatory modernization, pandemic resilience, and the growing role of Asia in global biomedical development.

The summit’s broader significance lies in how healthcare priorities across Asia are shifting. Governments are no longer framing healthcare solely as a public service issue. Increasingly, healthcare policy now intersects with economic competitiveness, manufacturing resilience, aging demographics, national security, and technological leadership.

Lo Chung-mau (featured) delivers the keynote address during the opening plenary session on pandemic preparedness at ASGH, following welcome remarks from Hong Kong Trade Development Council Chairman Frederick Ma Si-hang, opening remarks from Hong Kong Chief Executive John Lee Ka-chiu, and special remarks delivered on behalf of Zeng Yixin and by Deng Xiaoding. The opening discussions focused on pandemic preparedness, healthcare infrastructure, regulatory modernization, and the growing role of cross-border collaboration in Asia’s healthcare development strategy. Image: GeneOnline

Pandemic Preparedness Moves From Emergency Response to Permanent Infrastructure

The opening plenary session on pandemic preparedness reflected a noticeable evolution in how governments and global health leaders now discuss future outbreaks.

Rather than focusing primarily on emergency reaction mechanisms, speakers repeatedly emphasized long-term structural investment: surveillance systems, clinical trial infrastructure, regulatory coordination, public trust, and domestic manufacturing capacity.

Professor Lo Chung-mau opened the session by referencing a recent enterovirus outbreak on a cruise ship, using it as a reminder that pandemic threats remain active even as many countries move beyond COVID-era emergency policies.

“The next pandemic is not hypothetical,” Lo said. “It is a matter of when, not if.”

Lo outlined how Hong Kong expanded its territory-wide sewage surveillance system beyond COVID-19 to include pathogens such as influenza and polio, while also strengthening infection control training and establishing new emerging disease preparedness funding initiatives.

More significantly, he framed preparedness around infrastructure integration rather than isolated response mechanisms. That includes the creation of the Greater Bay Area International Clinical Trial Institute and the Real-World Study and Application Center, both designed to accelerate multicenter clinical trials and generate real-world evidence across the Guangdong-Hong Kong-Macao Greater Bay Area.

The strategy reflects a broader trend now emerging globally: governments increasingly view access to integrated clinical trial ecosystems as essential national infrastructure during health crises.

COVID-19 exposed how fragmented trial recruitment, disconnected medical data systems, and uneven regulatory standards delayed access to vaccines and therapeutics worldwide. Hong Kong’s response attempts to address those bottlenecks by linking its research institutions with mainland China’s patient population and healthcare infrastructure.

The scale matters. The Greater Bay Area’s combined population exceeds 87 million people, creating a significantly larger recruitment base for multinational pharmaceutical companies seeking faster clinical trial execution.

Clinical Trials Become a Strategic Economic Asset

Much of the summit focused on how regions compete to attract pharmaceutical R&D investment. Hong Kong officials repeatedly positioned the city as a gateway between China’s healthcare market and international regulatory systems under the “One Country, Two Systems” framework.

Chief Executive John Lee Ka-chiu described healthcare and biomedical innovation as core components of Hong Kong’s future economic strategy. He highlighted new investments into clinical trial infrastructure, startup funding, smart manufacturing, and regulatory modernization.

Among the most closely watched initiatives is Hong Kong’s “1+” drug registration mechanism, which allows certain drugs to receive approval after authorization from one recognized reference authority rather than two. Officials presented the policy as a way to shorten patient access timelines while strengthening Hong Kong’s role as a regional regulatory hub.

Lee also announced that the Hong Kong Center for Medical Products Regulation will launch by the end of the year, marking another step toward establishing a more independent pharmaceutical evaluation system.

These developments mirror a broader global race among governments attempting to position themselves as attractive destinations for biotechnology commercialization.

Increasingly, regions are competing not only on research quality, but also on:

• Regulatory speed and market access — Faster review pathways and integrated approval systems increasingly influence where pharmaceutical companies choose to conduct trials, launch products, and establish regional operations.
• Clinical data integration and research coordination — Governments are investing heavily in real-world evidence systems, cross-border data infrastructure, and multicenter trial networks to accelerate both drug development and regulatory decision-making.
• Manufacturing, financing, and commercialization readiness — Beyond scientific discovery alone, healthcare ecosystems now compete on their ability to scale production, attract investment capital, protect intellectual property, and move therapies into patients efficiently.

The summit repeatedly returned to one underlying question: which healthcare systems can move innovation into patients fastest while maintaining regulatory credibility?

China Signals Continued Expansion in Biopharma and Health Technology

Speakers from mainland China emphasized that healthcare innovation remains central to China’s long-term industrial strategy under the country’s upcoming 15th Five-Year Plan.

In remarks delivered on behalf of China’s National Health Commission, officials outlined goals that included increasing national life expectancy to 80 years, expanding innovative drug development, strengthening digital health infrastructure, and accelerating AI integration into clinical practice.

The speech also highlighted several sectors China increasingly views as strategically important for both economic growth and healthcare modernization:

• Advanced therapies and precision medicine — Officials pointed to gene editing, cell therapy, and innovative drug development as priority areas, reflecting how China continues to expand beyond generic manufacturing toward higher-value biomedical innovation and next-generation therapeutics.
• AI-enabled and digital healthcare systems — The integration of artificial intelligence, brain-computer interface technologies, and nationwide digital health infrastructure signals a broader push to modernize healthcare delivery while also improving efficiency across clinical workflows, diagnostics, and population health management.
• Global commercialization and industrial expansion — Chinese officials emphasized international collaboration, licensing activity, and cross-border partnerships as part of a strategy to position Chinese biopharma companies more competitively in global markets rather than focusing only on domestic healthcare demand.

One notable point involved the scale of China’s biopharmaceutical growth trajectory. Officials stated that China approved 76 innovative drugs in 2025 and reported more than US$130 billion in innovative drug licensing transactions.

At the same time, Chinese officials stressed international collaboration rather than domestic self-sufficiency alone.

Mr. Deng Xiaoding emphasized the importance of stable global pharmaceutical supply chains, mutual recognition of standards, and deeper cross-border industrial cooperation. His remarks reflected growing recognition that healthcare supply chains remain globally interdependent despite increasing geopolitical tensions.

That message carries particular relevance as countries reassess pharmaceutical manufacturing concentration risks following pandemic-era shortages.

Trust, Governance, and Public Communication Re-Emerge as Central Pandemic Lessons

While technology and investment dominated many sessions, several speakers shifted attention toward governance failures exposed during COVID-19.

Professor Ibrahim Abubakar argued that the pandemic revealed major weaknesses in international coordination and equitable access to vaccines and therapeutics. He noted that preparedness systems still suffer from cycles of “panic and neglect,” where governments invest heavily during crises before reducing funding afterward.

Abubakar also stressed that preparedness must account for broader societal disruption, not only infectious disease outcomes.

School closures, economic instability, and declining public trust all produced long-term consequences during COVID-19. Those effects, he argued, weakened confidence in institutions across multiple democracies and complicated future public health communication.

Dr. Kumanan Rasanathan expanded on that theme by focusing on governance structures inside countries. Drawing on research across multiple healthcare systems, he identified several capabilities public health agencies must maintain to remain effective during future outbreaks:

• Coordination across sectors and institutions — Pandemic preparedness cannot function solely within hospitals or health ministries. Governments need systems capable of coordinating public health agencies, clinical care networks, political leadership, and broader sectors such as education, transportation, and economic planning during crises.
• Scientific independence combined with political decision-making — Public health agencies require the authority to provide evidence-based recommendations independently, while governments must also maintain clear accountability for policy decisions that affect society at scale.
• Long-term public trust and sustainable financing — Speakers emphasized that trust cannot be built during emergencies alone. Transparent communication, community engagement, and stable domestic funding are necessary long before a crisis emerges if governments expect populations to follow public health guidance during future outbreaks.

“You cannot build trust during a crisis,” Rasanathan said, emphasizing that public confidence must exist before outbreaks occur.

The discussion reflected a broader post-pandemic shift in public health thinking. Increasingly, preparedness discussions now focus as much on governance, communication, and institutional legitimacy as on laboratory science alone.

Aging Populations and Healthcare Sustainability Shape Long-Term Planning

Beyond infectious disease preparedness, the summit repeatedly addressed demographic pressure as a major driver of healthcare restructuring across Asia. Officials from Hong Kong and mainland China both pointed to aging populations as a central policy challenge influencing healthcare spending, workforce planning, community care systems, and preventive medicine strategies.

That focus aligns with broader regional demographic trends. East Asia faces some of the world’s fastest-aging populations, forcing governments to rethink how healthcare systems can remain financially sustainable while demand rises.

Several summit discussions connected aging demographics directly to larger structural healthcare shifts:

• Greater reliance on digital and AI-supported healthcare delivery — Governments increasingly see automation, AI-assisted diagnostics, and remote monitoring systems as tools to manage growing healthcare demand while addressing workforce shortages tied to aging societies.
• Expansion of community and preventive care models — Speakers emphasized shifting healthcare systems away from purely hospital-centered treatment toward earlier intervention, home-based care, and preventive health management designed to reduce long-term strain on acute care infrastructure.
• Growth of the “silver economy” as a healthcare market driver — Aging populations are also reshaping pharmaceutical demand, medical device development, rehabilitation services, and health technology investment, turning demographic change into both a policy challenge and a major economic opportunity across Asia.

Rather than framing aging purely as a healthcare burden, speakers increasingly presented it as an economic transformation opportunity capable of reshaping pharmaceutical demand, healthcare delivery models, and investment priorities across Asia.

As the conference continues into its second day, discussions are expected to expand further into AI-enabled healthcare systems, gene and cell therapy commercialization, rare disease innovation, medical robotics, Chinese medicine standardization, and healthcare financing models. Together, the agenda reflects a broader shift taking place across the global healthcare industry: innovation alone is no longer enough. Increasingly, governments, healthcare systems, and industry leaders are competing on their ability to integrate research, regulation, manufacturing, financing, digital infrastructure, and patient access into scalable healthcare ecosystems capable of operating across borders and at population scale.

Author

Bernice Lottering